C Bertolotto
Overview
Explore the profile of C Bertolotto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1253
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hamerstehl A, Gadiollet E, Martel A, Groulier A, Aloi D, Nguyen A, et al.
J Fr Ophtalmol
. 2024 Nov;
48(1):104351.
PMID: 39515034
Purpose: Treatment delays due to the COVID-19 pandemic in uveal melanoma (UM) patients have led to an increased rate of enucleations in Europe. The impact of multiple COVID-19 lockdowns on...
2.
Martel A, Nahon-Esteve S, Gastaud L, Bertolotto C, Lassalle S, Baillif S, et al.
Ophthalmic Epidemiol
. 2020 Jul;
28(2):169-174.
PMID: 32693661
Purpose: Orbital exenteration is a radical and disfiguring surgery mainly performed for treating orbital malignancies. Recently, several studies found favorable results in terms of overall survival with eye-sparing surgeries combined...
3.
Martel A, Hamedani M, Lagier J, Bertolotto C, Gastaud L, Poissonnet G
J Fr Ophtalmol
. 2019 Dec;
43(2):152-174.
PMID: 31831277
Introduction: Orbital exenteration is a radical anatomically and psychologically disfiguring procedure. It is mostly performed for management of orbital cancers or cancers with orbital involvement. The lack of benefit in...
4.
Leclerc J, Ballotti R, Bertolotto C
Oncogene
. 2017 Aug;
36(48):6659-6667.
PMID: 28825724
Cutaneous melanoma is a deadly skin cancer that originates from melanocytes. The development of cutaneous melanoma involves a complex interaction between environmental factors, mainly ultraviolet radiation from sunlight, and genetic...
5.
De Donatis G, Le Pape E, Pierron A, Cheli Y, Hofman V, Hofman P, et al.
Oncogene
. 2016 May;
35(21):2813.
PMID: 27225420
No abstract available.
6.
De Donatis G, Le Pape E, Pierron A, Cheli Y, Hofman V, Hofman P, et al.
Oncogene
. 2015 Sep;
35(21):2735-45.
PMID: 26364600
Enhancer of Zeste homologue 2 (EZH2) belongs to the polycomb repressive complex 2 and catalyzes the methylation of histone H3 lysine 27. These pivotal epigenetic marks are altered in many...
7.
Cheli Y, Giuliano S, Fenouille N, Allegra M, Hofman V, Hofman P, et al.
Oncogene
. 2011 Oct;
31(19):2461-70.
PMID: 21996743
Melanomas are very aggressive neoplasms with notorious resistance to therapeutics. It was recently proposed that the remarkable phenotypic plasticity of melanoma cells allows for the rapid development of both resistance...
8.
Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, et al.
Cell Death Dis
. 2011 Sep;
2:e199.
PMID: 21881601
Metformin is the most widely used antidiabetic drug because of its proven efficacy and limited secondary effects. Interestingly, recent studies have reported that metformin can block the growth of different...
9.
Cheli Y, Giuliano S, Guiliano S, Botton T, Rocchi S, Hofman V, et al.
Oncogene
. 2011 Feb;
30(20):2307-18.
PMID: 21278797
In melanoma, as well as in other solid tumors, the cells within a given tumor exhibit strong morphological, functional and molecular heterogeneity that might reflect the existence of different cancer...
10.
Strub T, Giuliano S, Ye T, Bonet C, Keime C, Kobi D, et al.
Oncogene
. 2011 Jan;
30(20):2319-32.
PMID: 21258399
Malignant melanoma is an aggressive cancer known for its notorious resistance to most current therapies. The basic helix-loop-helix microphthalmia transcription factor (MITF) is the master regulator determining the identity and...